Loading…
The Oncology Institute, Inc. is projected to rise to $6.56 by 2027, a +35% move from its current price of $4.86. TOI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $4.69 | $4.86 | $5.05 | +0.09% |
| Aug 4 | $4.62 | $4.87 | $5.13 | +0.18% |
| Aug 5 | $4.57 | $4.87 | $5.19 | +0.28% |
| Aug 6 | $4.53 | $4.88 | $5.25 | +0.37% |
| Aug 7 | $4.50 | $4.88 | $5.30 | +0.46% |
| Aug 8 | $4.46 | $4.89 | $5.35 | +0.55% |
| Aug 9 | $4.44 | $4.89 | $5.39 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.44 | $4.89 | $5.39 | +0.64% |
| Week 2 | $4.29 | $4.92 | $5.65 | +1.29% |
| Week 3 | $4.18 | $4.95 | $5.87 | +1.94% |
| Week 4 | $4.10 | $4.99 | $6.06 | +2.60% |
| Week 5 | $4.03 | $5.02 | $6.24 | +3.26% |
| Week 6 | $3.98 | $5.05 | $6.41 | +3.93% |
| Week 7 | $3.93 | $5.08 | $6.58 | +4.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
The Oncology Institute, Inc. (TOI) is a healthcare company focused on oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services.
It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc.
was founded in 2007 and is headquartered in Cerritos, California.
The Oncology Institute, Inc. trades at $5.07 per share and has a market cap of $506.91M, ranking 2971. This places TOI among smaller-cap healthcare stocks with a focused oncology services profile.
Near-term outlook shows a neutral stance for 2026 with an average price of $5.07 and sentiment labeled NEUTRAL, suggesting limited near-term upside in the base year but potential for upside thereafter.
From 2027 onward, the forecasted path is bullish, with the average price advancing to $6.83 in 2027 and rising to $10.12 by 2030. Long-range forecasts project significant upside, with a 2040 average of $49.04 and a 2050 average of $96.75, signaling substantial long-term appreciation potential in the modeled outlook.
A major floor 41.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 29.2% above — a clean break opens room to run.
A major ceiling 40.2% above — clearing it would confirm fresh momentum.
Key TOI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TOI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.97 | Sell | $4.97 | Sell |
| MA 10 | $5.11 | Sell | $5.10 | Sell |
| MA 20 | $5.43 | Sell | $5.22 | Sell |
| MA 50 | $5.14 | Sell | $5.02 | Sell |
| MA 100 | $4.29 | Buy | $4.54 | Buy |
| MA 200 | $3.85 | Buy | $3.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.09 | Neutral |
| Stoch RSI (14) | 9.74 | Buy |
| CCI (20) | -108.62 | Sell |
| Williams %R (14) | -94.04 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -14.13 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 5.96 | Buy |
| TRIX (15) | 0.08 | Buy |
| Awesome (5,34) | -0.39 | Sell |
| Ultimate (7,14,28) | 34.60 | Neutral |
| Momentum (10) | -0.49 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 4.85 | Buy |
| ADX (14) | 16.82 | Neutral |
| ATR (14) | 0.20 | Info |
The 30-day technical picture shows a bullish tilt in the near term, with the price trading just above the SMA50 of $5.03 while RSI(14) sits at 40. This setup can indicate a constructive bias as price hovers near the short-term moving average.
Key support is listed at $4.68 and resistance at $6.28, framing a near-term range that spans roughly from $3.98 to $6.46 over the past 30 days. The stock’s annualized volatility is elevated at 70%, underscoring the potential for outsized moves in either direction while the bullish sentiment persists.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.38 | $4.86 | $6.95 | 0% | Neutral | |
| $5.06 | $6.56 | $9.08 | +35% | Bullish | |
| $6.40 | $8.63 | $12.53 | +78% | Bullish | |
| $6.60 | $9.20 | $13.86 | +89% | Bullish | |
| $6.85 | $9.83 | $15.28 | +102% | Bullish | |
| $8.63 | $12.72 | $20.32 | +162% | Bullish | |
| $10.09 | $15.25 | $24.96 | +214% | Bullish | |
| $13.13 | $20.33 | $33.99 | +318% | Bullish | |
| $15.21 | $24.09 | $41.08 | +396% | Bullish | |
| $14.86 | $24.06 | $41.79 | +395% | Bullish | |
| $26.64 | $47.77 | $89.51 | +883% | Bullish | |
| $44.69 | $96.39 | $201.35 | +18.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.38 | $4.86 | $6.03 | +0.00% |
| September 2026 | $4.18 | $5.00 | $6.19 | +2.93% |
| October 2026 | $4.38 | $5.28 | $6.63 | +5.63% |
| November 2026 | $4.50 | $5.48 | $6.95 | +3.65% |
| December 2026 | $4.43 | $5.42 | $6.95 | -0.96% |
Click any year to see its month-by-month TOI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The TOI price prediction for 2026 points to an average of $4.86 (low $2.38, high $6.95) — a potential gain of 0% on today's $4.86. A consolidation phase looks the most probable path here.
In 2027, TOI is projected to trade between $5.06 and $9.08, averaging $6.56 — a potential gain of +35% from today's $4.86. That is up +35% on the projected 2026 average. Momentum favours further upside here.
The Oncology Institute, Inc.'s 2028 outlook centres on $8.63, within a $6.40 to $12.53 range. That is up +32% on the projected 2027 average. That marks a +78% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, TOI could reach as high as $13.86, with a base case around $9.20 and support toward $6.60 — roughly +89% from $4.86. Momentum favours further upside here.
Expect TOI to range from $6.85 to $15.28 through 2030. The $9.83 average target implies a +102% move from current prices. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The TOI price prediction for 2031 points to an average of $12.72 (low $8.63, high $20.32) — a potential gain of +162% on today's $4.86. Momentum favours further upside here.
In 2032, TOI is projected to trade between $10.09 and $24.96, averaging $15.25 — a potential gain of +214% from today's $4.86. That is up +20% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The Oncology Institute, Inc.'s 2033 outlook centres on $20.33, within a $13.13 to $33.99 range. That is up +33% on the projected 2032 average. That marks a +318% change versus current levels. Momentum favours further upside here.
By 2034, TOI could reach as high as $41.08, with a base case around $24.09 and support toward $15.21 — roughly +396% from $4.86. Buyers look set to stay in control over this stretch.
Expect TOI to range from $14.86 to $41.79 through 2035. The $24.06 average target implies a +395% move from current prices. That is 0% versus the projected 2034 average. Momentum favours further upside here.
The TOI price prediction for 2040 points to an average of $47.77 (low $26.64, high $89.51) — a potential gain of +883% on today's $4.86. Buyers look set to stay in control over this stretch.
In 2050, TOI is projected to trade between $44.69 and $201.35, averaging $96.39 — a potential gain of +18.8x from today's $4.86. That is up +102% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in TOI today (≈ 205.761317 TOI) could be worth
$19,834.31
+$18,834.31 (+1883%) by 2050 · US Dollar
Based on the average projected TOI price of $96.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TOIwould be worth at today's price.
$1,000 invested in TOI on Jul 31, 2025 (≈ 272.479558 TOI) would be worth
$1,324.25
+$324.25 (+32.4%) today · 1.32× · US Dollar
Based on a TOI entry price of $3.67 vs. today's $4.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.98 | $975.9 | -2.4% |
| 1 month ago | $5.51 | $882.03 | -11.8% |
| 3 months ago | $4.05 | $1,200 | +20.0% |
| 6 months ago | $2.68 | $1,813.43 | +81.3% |
| 1 year ago | $3.67 | $1,324.25 | +32.4% |
| All time (5.0y) ago | $9.9 | $490.91 | -50.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TOI forecast.
Our base-case forecast reaches $9.70 around 2030.
Implied market cap at $9.70: $969.83M
The multi-year forecast shows a steady path of upside with a series of rising averages and expanding upside potential. In 2026 the avg is $5.07 with ROI 0 and sentiment NEUTRAL, setting a base level. By 2027 the avg rises to $6.83 (ROI 34.7) with a bullish outlook continuing through 2028 at $8.78 (ROI 73.1) and 2029 at $9.30 (ROI 83.5).
The 2030 avg is $10.12 (ROI 99.7) with continued bullish momentum.
Beyond 2031–2035 the forecast shows further gains: 2031 avg $13.13 (ROI 159), 2032 avg $15.98 (ROI 215.1), 2033 avg $21.08 (ROI 315.8), 2034 avg $24.44 (ROI 382), and 2035 avg $24.32 (ROI 379.6). The long-range horizon highlights substantial upside with 2040 avg $49.04 (ROI 867.2) and 2050 avg $96.75 (ROI 1808.2), all under a bullish sentiment. These figures are estimates and not guarantees, and actual results can vary with market conditions and company performance.
Tap a question to reveal the answer.
The forecast for 2030 lists an average price of $10.12, with a min of $7.06 and a max of $15.74, and a forecasted ROI of 99.7 with a bullish sentiment.
Forecasts show a transition from Neutral in 2026 (avg $5.07, ROI 0) to Bullish beginning in 2027 (avg $6.83, ROI 34.7) and continuing to rise toward 2050 (avg $96.75, ROI 1808.2). These are estimates and not guarantees.
Yes. The 2031 forecast lists a max of $20.96 with an average of $13.13, indicating the potential to exceed $20 in the mid-range horizon.
Current price: $5.07. Market cap: $506.91M.
The 30-day range is $3.98 to $6.46.
The Oncology Institute, Inc. Community Discussion
0Share your The Oncology Institute, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.